While PDLIM2 is epigenetically repressed in human lung cancer, associating with therapeutic resistance and poor prognosis, its global or lung epithelial-specific deletion in mice leads to lung cancer development, chemoresistance, and complete resistance to anti-PD-1 and epigenetic drugs. The gene discussed is PDLIM2; the disease is lung carcinoma.